MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jjcc.2022.01.005

Медицинская библиотека · Journal of cardiology · 2022

D-dimer levels in patients with nonvalvular atrial fibrillation and acute heart failure treated with edoxaban.

Kida Keisuke, Nabeta Takeru, Ishida Miwa, Shiono Takaaki, Suzuki Norio, Doi Shunichi, Tsukahara Maya, Ohta Yuki, Kimura Tetsuya, Morishima Yoshiyuki, Takita Atsushi, Matsumoto Naoki, Akashi Yoshihiro J, Ako Junya, Inomata Takayuki

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

D-dimer levels can predict ischemic stroke in patients with acute heart failure (AHF). However, the effects of direct oral anticoagulants on D-dimer levels have not been investigated during admission for AHF in patients with atrial fibrillation (AF). This study examined D-dimer levels immediately after admission and following edoxaban initiation as a sub-analysis of a multi-center study that investigated the pharmacokinetics and pharmacodynamics of edoxaban in patients with nonvalvular AF (NVAF) and AHF.

METHODS

Hospitalized patients with NVAF and AHF received edoxaban according to the label. The primary measure was the change in D-dimer levels on 7 consecutive days after admission for AHF. We also investigated differences according to prior edoxaban use (de novo at the time of admission or continuation).

RESULTS

In 10/13 (76.9%) de novo patients, D-dimer levels exceeded the reference value (1.0 µg/mL) at admission (mean, 2.12 µg/mL) and subsequently decreased in 9 patients (at final blood sampling: mean, 1.12 µg/mL); 1 patient did not fall below the reference value due to stasis dermatitis. In the continuation group, most patients had D-dimer levels below the reference value from Day 1 (mean, 0.93 µg/mL), and levels remained stable or decreased (at final blood sampling: mean, 0.49 µg/mL). No events of stroke were observed.

CONCLUSIONS

D-dimer levels may be elevated in patients with NVAF and AHF, particularly in those without prior anticoagulant treatment. Edoxaban may be effective for lowering and keeping D-dimer levels, a biomarker for predicting ischemic stroke, below the reference value in patients with NVAF and AHF.

Для цитирования: Kida Keisuke, Nabeta Takeru, Ishida Miwa, Shiono Takaaki, Suzuki Norio, Doi Shunichi, Tsukahara Maya, Ohta Yuki, Kimura Tetsuya, Morishima Yoshiyuki, Takita Atsushi, Matsumoto Naoki, Akashi Yoshihiro J, Ako Junya, Inomata Takayuki. D-dimer levels in patients with nonvalvular atrial fibrillation and acute heart failure treated with edoxaban.. Journal of cardiology. 2022. DOI: 10.1016/j.jjcc.2022.01.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.